Scientists Take Aim at Disease-Causing RNAs Using Small-Molecule Drugs
Scientists Take Aim at Disease-Causing RNAs Using Small-Molecule Drugs
Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.
Scientists Take Aim at Disease-Causing RNAs Using Small-Molecule Drugs
Scientists Take Aim at Disease-Causing RNAs Using Small-Molecule Drugs

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

Bio Business
Companies Use CRISPR to Improve Crops
Companies Use CRISPR to Improve Crops
Ashley P. Taylor | Feb 1, 2019
The agritech industry is editing plant genomes to feed a growing population, expand the produce aisle, and make tastier, more convenient food products.
The UK Pharmaceutical Industry Braces for Brexit
The UK Pharmaceutical Industry Braces for Brexit
Diana Kwon | Oct 12, 2018
As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.
Startups Plan the Health Data Gold Rush
Startups Plan the Health Data Gold Rush
Shawna Williams | Oct 1, 2018
Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.
New ALS Therapies Move Closer to the ClinicNew ALS Therapies Move Closer to the Clinic
New ALS Therapies Move Closer to the Clinic
Jenny Rood | Sep 1, 2018
After two decades of failure, novel scientific insights and technical progress are spurring meaningful innovation in the field.
Bringing the Internet of Things into the Lab
Bringing the Internet of Things into the Lab
Abby Olena | Jun 1, 2018
The IoT can link up many facets of research—from laboratory equipment to ideas—but scientists must be ready for the questions its implementation could raise.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
The Quest for Safer Opioid Drugs
The Quest for Safer Opioid Drugs
Jenny Rood | Jan 1, 2018
From basic research in academic labs to Phase 3 clinical trials, myriad efforts are underway to divorce opioids' pain-relieving potential from their undesirable downsides.
Flux and Uncertainty in the CRISPR Patent Landscape
Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
Accessing Drugs for Medical Aid-in-Dying
Accessing Drugs for Medical Aid-in-Dying
Catherine Offord | Aug 16, 2017
A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.